I'm not sure when I would guess the FA comes in. I still think there is a good chance that Apabetalone + Rosuvastatin (crestor) behaves differently than Apabetalone + atorvastatin (Lipitor) as it did in plaque reduction in the post hocs. That being said I don't recall MACE differentiation in post hocs. I do find it interesting that RVX filed for a patent on Apabetalone + Rosuvastatin but not for Apabetalone + atorvastatin that I'm aware of. I wonder if the company expects a difference between the two subgroups?  If there is a difference how will it affect the FA?